The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

A wide-reaching Trump Administration order disrupted systems nationwide and left millions unsure if they will lose access to jobs, housing and health care. Institutions in Long Beach are scrambling to ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

CNW/ - Although significant progress has been made in the past several decades in reducing smoking rates in Canada , the Council of Chief Medical ...

A former central banker, a one-time deputy PM, and members of parliament are all eyeing the top job. Speaking to business leaders in Davos, Trump also repeated his jibe that Canada could become a ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

ROCHESTER, Minn. & SUNNYVALE, Calif.--(BUSINESS WIRE)--Cerebras Systems, in collaboration with Mayo Clinic, announced significant progress in developing artificial intelligence tools to advance ...

Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...

The investigation comes after Italian authorities freed a Libyan national wanted by the ICC. Italian authorities released the director of a notorious detention camp who had been arrested in Turin ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early studies have found to be safe and capable of engaging its target. Eli Lilly on ...